GSK selects Witty as next CEO

Share this article:

GlaxoSmithKline (GSK) has tapped Englishman Andrew Witty to succeed Jean Pierre Garnier as CEO in May.

At age 43, Witty will become the youngest–ever leader of Europe's largest drug maker at a time when the company is seeking to reinvigorate its sales growth.

Witty has worked for the UK-based GSK in the US, Asia and Africa and became president of European operations in 2003.

Witty joined GSK in 1985 in the UK where he held positions as director of pharmacy and distribution and international product manager.

Outside the UK, he was director for south and east Africa and marketing manager for GSK's US unit before moving to Singapore as an Asian SVP.

Garnier, who turns 60 at the end of October, joined SmithKline Beecham in 1990 as president of its North American pharmaceuticals division. He was named CEO in 2000.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.